AbbVie agreed on June 22, 2026 to acquire Apogee Therapeutics for $135.11 per share in cash — a total of $10.9 billion. This is AbbVie's biggest purchase in more than five years, according to CNBC and AbbVie's announcement.

The price AbbVie is paying is 49% higher than Apogee's stock price the day before. When the deal was announced, Apogee's stock jumped to $132.65 — very close to the deal price of $135.11. That small gap between what traders are willing to pay today and the final deal price reflects the risk that the deal might not close, not doubt about whether the purchase makes sense.

So what is AbbVie buying? The company is after zumilokibart, an experimental drug being developed to treat atopic dermatitis — a type of inflammatory skin condition that causes itching and irritation, per Investing.com. The drug is a monoclonal antibody, which is a type of protein designed in the lab to attack a specific target in your body. Think of it as a precision tool rather than a general medicine that works all over the place.

Why does AbbVie need this drug? The company makes other popular immunology drugs — medicines for immune-system and inflammatory diseases — but those drugs have faced cheaper competition. Zumilokibart could help AbbVie compete in the skin disease market, where a rival drug called Dupixent already leads. But here's the key: zumilokibart is not approved yet. It is still being tested in late-stage clinical trials. AbbVie is betting that it will work.

How much of a bet? AbbVie says the deal will shrink its profits per share by about 14%. That means shareholders will earn less profit per share in the short term, even though the company bought something valuable. For a large pharmaceutical company, accepting a 14% profit drop to buy a drug that might be successful is a deliberate choice. The company is betting on the future, not on money it will make next year.

Can AbbVie afford this? Yes. The company generated about $22 billion in cash from its normal business operations in 2024. Paying $10.9 billion in cash is a big check, but not one the company cannot write. Still, investors will be watching to make sure AbbVie does not borrow too much to pay for this deal.

Is zumilokibart guaranteed to win? No. The atopic dermatitis market is crowded. Dupixent, made by Sanofi and Regeneron, already dominates it. Other companies are also developing competing drugs. Zumilokibart needs to show it works better — or differently — than what is already out there. AbbVie is paying for the chance to find out, but a chance is not a promise.

When will the deal close? AbbVie has not announced a date yet. Deals paid for entirely in cash typically take six to nine months to finalize, once government regulators have approved them. Both companies mostly operate in the United States, and Apogee does not yet sell any drugs in the market, so major regulatory obstacles are unlikely — though regulators are currently scrutinizing big pharmaceutical deals, so nothing is guaranteed.